{
  "nctId": "NCT02106442",
  "briefTitle": "36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets",
  "officialTitle": "36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets",
  "protocolDocument": {
    "nctId": "NCT02106442",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-06-02",
    "uploadDate": "2019-04-23T01:48",
    "size": 2362039,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02106442/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 579,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-05-13",
    "completionDate": "2018-04-30",
    "primaryCompletionDate": "2018-04-30",
    "firstSubmitDate": "2014-04-03",
    "firstPostDate": "2014-04-08"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nOsteoporosis patients who meet all the following criteria:\n\n1. Patients with 1 to 4 confirmed vertebral body fractures in the T4-L4 region by thoracic and lumbar spine X-ray examination at screening (within 3 months before the start of administration of sodium risedronate 75 mg tablets)\n2. Male and postmenopausal female patients aged 50 years or older\n3. Ambulatory outpatients\n\nExclusion Criteria:\n\n\\-",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "50 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Cumulative Percentage of Participants With New or Worsening Vertebral Body Fractures",
        "description": "The cumulative data was collected between baseline and Month 36, and reported for the following time points: baseline, Months 6, 12, 18, 24, 30, and 36.",
        "timeFrame": "From baseline up to Month 36"
      }
    ],
    "secondary": [
      {
        "measure": "Cumulative Percentage of Participants With Non-Vertebral Body Fractures",
        "description": "The cumulative data was collected between baseline and Month 36, and reported for the following time points: baseline, Months 6, 12, 18, 24, 30, and 36.",
        "timeFrame": "From baseline up to Month 36"
      },
      {
        "measure": "Cumulative Percentage of Participants With Femur Fractures",
        "description": "The cumulative data was collected between baseline and Month 36, and reported for the following time points: baseline, Months 6, 12, 18, 24, 30, and 36.",
        "timeFrame": "From baseline up to Month 36"
      },
      {
        "measure": "Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment (up to Month 36)",
        "description": "BMD was measured by dual-energy X-ray absorptiometry.",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Femur Neck BMD at Final Assessment (up to Month 36)",
        "description": "BMD was measured by dual-energy X-ray absorptiometry.",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Total Proximal Femur BMD at Final Assessment (up to Month 36)",
        "description": "BMD was measured by dual-energy X-ray absorptiometry.",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Radius BMD at Final Assessment (up to Month 36)",
        "description": "BMD was measured by dual-energy X-ray absorptiometry.",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Change From Baseline in Height at Final Assessment (up to Month 36)",
        "timeFrame": "Baseline and final assessment (up to Month 36)"
      },
      {
        "measure": "Number of Participants Who Had Lumbar Backache at Final Assessment (up to Month 36)",
        "timeFrame": "Final assessment (up to Month 36)"
      },
      {
        "measure": "Number of Participants Who Had One or More Adverse Drug Reactions",
        "description": "Adverse drug reaction refers to adverse events related to the administered drug.",
        "timeFrame": "Up to Month 36"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 14,
      "otherCount": 0,
      "totalCount": 15
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:04.275Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}